Evaluating How DNA Repair Changes Affect Radium-223 Therapy in Men with Bone-Metastatic Castration-Resistant Prostate Cancer

What this Trial Is About

Researchers are studying how changes in the DNA repair pathway affect the treatment of men with castration-resistant prostate cancer that has spread to the bones. This condition is common in men and is a leading cause of cancer death. The study focuses on how the approved drug radium-223, which causes DNA damage to cancer cells, works depending on these DNA repair changes. Participants receive radium-223 given intravenously once every 4 weeks for up to 6 cycles as part of their standard care. Blood samples are collected every 1 to 3 months during this treatment period. After completing the treatment, participants are followed up every 3 months for up to 5 years to monitor their health and response. During the study, participants will undergo blood tests and complete questionnaires. Researchers will measure response rates to treatment within one year and track overall survival for up to five years. They will also assess pain, quality of life, use of pain medication, and any side effects. The total participation time includes treatment cycles and long-term follow-up to better understand outcomes.

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer